pharma · Chronic Inflammatory Demyelinating Polyneuropathy · Multifocal Motor Neuropathy · DNTH
Dianthus Therapeutics, Inc
Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc is a pharma organization headquartered in New York City, USA. It trades on NYSE under ticker DNTH. Primary therapeutic focus areas include Chronic Inflammatory Demyelinating Polyneuropathy, Mul
New York City, USA HQ
111 Employees
Public company Type
DNTH · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York City, USA
- Employees
- 111
- Programs
- 6
- Drugs
- 12
- Patents
- 2
DNTH103
Phase 2 · small molecule · Myasthenia Gravis, Generalized
DNTH103 for Myasthenia Gravis, Generalized is a Phase 2 program (small_molecule) at Dianthus Therapeutics, Inc. /DE/ with 1 ClinicalTrials.gov record(s).
Internal code DNTH103-MG-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dianthus Therapeutics, Inc. /DE/
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Myasthenia Gravis, Generalized
- Status
- active
- Trials
- 1